Bone Microarchitecture in the Transplant Patient
TRANSOS
Longitudinal Monitoring of Bone Microarchitecture by High Resolution Peripheral Quantitative Computed Tomography of (HR-pQCT) in the Transplant Patient
2 other identifiers
interventional
137
1 country
3
Brief Summary
The optimal management of calcium and phosphate metabolism regulation in chronic kidney disease (CKD) is important in preventing fracture risk and vascular calcification and thus morbidity and mortality, global and vascular. Kidney transplant in a CKD context, usually with a pre-existing underlying renal osteodystrophy, malnutrition, chronic inflammation, hypogonadism and immunosuppression protocols still often made up of high-dose corticosteroid therapy, are all theoretical factors of post-transplantation bone disease. For other solid organ transplants, even though there is generally no underlying renal osteodystrophy before the transplant, the proportion of osteoporotic patients at the time of transplant is substantial. The bone risk in the immediate post-transplant period is notable. Patients' follow-up is based on biological, radiological and histological tools. Bone densitometry (DXA) is used to measure bone mass. However, recent international recommendations do not consider DXA as a valid tool to assess bone health in CKD patients. Moreover, it is less informative than peripheral quantitative tomography resolution (HR-pQCT). This latest technique, available in Lyon and Saint-Etienne, is more precise, allowing a three-dimensional study of the trabecular microarchitecture and compartmental volumetric bone density (total, cortical, trabecular), while similar to DXA in terms of radiation (less than 5 μSv). The prevention of cardiovascular risk factors is also part of the daily care of patients with a regular cardiac monitoring (heart ultrasound) and vascular (blood pressure, Doppler of the supra-aortic trunks). TRANSOS study aims to evaluate in a prospective cohort (longitudinal follow-up of 6 months), the bone status in patients receiving solid organ transplantation in the University Hospitals of Lyon and Saint-Etienne, using DXA and HR-pQCT (at baseline and month 6), in combination with classical biological and cardiovascular monitoring. Transplantation is an important activity in these two hospitals and this protocol provides the same bone follow-up for all solid organ transplants, with a reliable, efficient, non-invasive and low-dose radiation tool. The primary objective of TRANSOS study is to evaluate changes in tibial cortical density between the baseline and the 6th month post-transplant measured by HR-pQCT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2016
Longer than P75 for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 25, 2016
CompletedFirst Posted
Study publicly available on registry
April 6, 2016
CompletedStudy Start
First participant enrolled
June 7, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 8, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 8, 2020
CompletedAugust 22, 2025
November 1, 2020
4.3 years
March 25, 2016
August 20, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Tibial cortical density measured by HR-pQCT
at 6 months
Secondary Outcomes (25)
trabecular bone area measured by HR-pQCT
at 6 months
total bone area measured by HR-pQCT
at 6 months
trabecular number measured by HR-pQCT
at 6 months
trabecular thickness measured by HR-pQCT
at 6 months
trabecular separation measured by HR-pQCT
at 6 months
- +20 more secondary outcomes
Study Arms (1)
Tibial cortical density evaluation
EXPERIMENTALInterventions
Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
Eligibility Criteria
You may qualify if:
- Patient over 10 year-old
- Patient receiving a first solid organ transplant within involved hospitals (Lyon, Saint Etienne): kidney, heart, kidney-pancreas, lung
- Informed consent signed by the patients or their parents (minors)
You may not qualify if:
- No health cover
- Ongoing pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Hôpital Femme Mère Enfant
Bron, France
Hopital Edouard Herriot
Lyon, France
CHU Saint Etienne
Saint-Etienne, France
Related Publications (1)
De Mul A, Leclerc AS, Ginhoux T, Levi C, Confavreux C, Aurelle M, Portefaix A, Bacchetta J. Changes in bone density and microarchitecture in adolescents undergoing a first kidney transplantation: a prospective study. Eur J Pediatr. 2024 Dec;183(12):5303-5312. doi: 10.1007/s00431-024-05777-z. Epub 2024 Oct 9.
PMID: 39384649RESULT
Study Officials
- PRINCIPAL INVESTIGATOR
Charlene LEVI, Doctor
Hospices Civils de Lyon
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 25, 2016
First Posted
April 6, 2016
Study Start
June 7, 2016
Primary Completion
October 8, 2020
Study Completion
October 8, 2020
Last Updated
August 22, 2025
Record last verified: 2020-11